Podiatrists in Glastonbury, CT Accepting Medicare

6 Podiatrists found. Showing 1 - 6

Hartford Specialists Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 330 Western Blvd, Glastonbury, CT 06033 Phone: 860-547-0616    Fax: 860-524-2655

Jennifer Decker, Dpm Podiatrist - Foot & Ankle Surgery Medicare: Not Enrolled in Medicare Practice Location: 300 Hebron Ave, Suite 211, Glastonbury, CT 06033 Phone: 860-657-3668    Fax: 860-657-1678

Hartford Healthcare Medical Group, Inc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 330 Western Blvd, Glastonbury, CT 06033 Phone: 860-246-2071

Steven Harrison Blume, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 129 Peach Tree Rd, Glastonbury, CT 06033 Phone: 860-633-4032    Fax: 860-633-3063

Kimberly Inocco, DPM Podiatrist - Foot & Ankle Surgery Medicare: Medicare Enrolled Practice Location: 300 Hebron Ave Ste 104, Glastonbury, CT 06033 Phone: 860-633-9004

Connecticut Foot Care Centers Llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 300 Hebron Ave, Suite 105, Glastonbury, CT 06033 Phone: 860-633-6749    Fax: 860-633-8168

News Archive

Georgia researchers create map of the human brain

University of Georgia researchers have developed a map of the human brain that shows great promise as a new guide to the inner workings of the body's most complex and critical organ.

The COVID-19 vaccine pipeline

Major nations are in a race to make an effective vaccine that could help treat the novel coronavirus infection COVID-19. As hundreds of thousands are infected across the world and over sixteen thousand killed, the pandemic shows no signs of relenting.

Elsevier, KIT sign MoU to provide developing country researchers access to ScienceDirect and Scopus

Elsevier and the Royal Tropical Institute (KIT) in Amsterdam announced on 26th of August the signing of a Memorandum of Understanding (MoU) providing 150 researchers working in least-developed and low-income countries (for example Benin, Mozambique, Ethiopia, Togo etc.) with access to ScienceDirect and Scopus, Elsevier's online scientific research platform and flagship abstract and citation database.

Australia's Mesoblast receives nod to start first European trial of allogeneic stem cell treatment for heart attacks

Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor™ in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor™ is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

Read more Medical News

› Verified 3 days ago